CPHI China Pharma Holdings, Inc.
Financings ·
China Pharma Holdings, Inc. priced a registered direct offering of 2.5 million common shares at $2 per share, for gross proceeds of $5 million before placement agent fees and other expenses. FT Global Capital, Inc. is the exclusive placement agent.
China Pharma says it will file its 2025 annual report within fifteen calendar days after March 31, 2026. Its estimates show revenue of $4.1 million and a net loss of about $3.19 million, and its auditors have raised going-concern doubt before.
China Pharma's subsidiary Helpson agreed on February 26, 2026 to buy a sublingual tablet patent for $6.93 million, paid in 12,600,000 unregistered shares at $0.55 each. The company has a going-concern warning in its latest annual report.
China Pharma Holdings, Inc. is a Nevada holding company whose operations are conducted through its wholly owned subsidiary Hainan Helpson Medical and Biotechnology Co., Ltd. (Helpson) and Helpson's subsidiaries in China. Through Helpson, the company develops, manufactures and markets pharmaceutical products for a variety of high-incidence and high-mortality diseases in the People's Republic of China. Helpson makes dry powder injectables, liquid injectables, tablets, capsules and cephalosporin oral solutions. Most of its products are sold on a prescription basis, and all have been approved for at least one therapeutic indication by the National Medical Products Administration. As of December 31, 2025, the company held rights to manufacture 19 pharmaceutical products in three categories: basic generic drugs, first-to-market generic drugs, and modern Traditional Chinese Medicines. Helpson operates two production facilities in Haikou, Hainan Province, and sells directly to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistic companies.
| Product or program | What it is | Stage |
|---|---|---|
| Basic generic drugs | Common drugs with very large market demand in the PRC | Approved for at least one indication by the NMPA |
| First-to-market generic drugs | Generic drugs that are new to the PRC marketplace | Approved for at least one indication by the NMPA |
| Modern Traditional Chinese Medicines | Plant-based medicinal compounds widely used in the PRC | Approved for at least one indication by the NMPA |
| Injectables, tablets, capsules and oral solutions | Dry powder and liquid injectables, tablets, capsules and cephalosporin oral solutions | Approved for at least one indication by the NMPA |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $4.1 million | $4.5 million |
| Research and development | $280,901 | $283,942 |
| Net income (loss) | -$3.2 million | -$4.7 million |
| Cash from operations | $148,261 | -$406,063 |
| Cash and equivalents | $345,112 | $626,879 |
Our latest story on this, dated Apr 1, 2026: "China Pharma Holdings files NT 10-K for late annual report, estimates $3.19 million net loss". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 22, 2026: "China Pharma prices $5 million registered direct offering". The story links the filing or release it is based on. Read the story.
China Pharma Holdings, Inc. trades under the ticker CPHI on AMEX.
China Pharma Holdings, Inc. is listed on AMEX.
The SEC Central Index Key (CIK) for China Pharma Holdings, Inc. is 1106644. Its filings are on SEC EDGAR.
43,022,002 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-14.
Our directory records China Pharma Holdings, Inc. under China.
Our directory classifies China Pharma Holdings, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for China Pharma Holdings, Inc. is US16941T4013.
aibio.space lists China Pharma Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
China Pharma Holdings, Inc. is a Nevada holding company whose operations are conducted through its wholly owned subsidiary Hainan Helpson Medical and Biotechnology Co., Ltd. (Helpson) and Helpson's subsidiaries in China. Through Helpson, the company develops, manufactures and markets pharmaceutical products for a variety of high-incidence and high-mortality diseases in the People's Republic of China.
Basic generic drugs: Common drugs with very large market demand in the PRC Stage: Approved for at least one indication by the NMPA.
First-to-market generic drugs: Generic drugs that are new to the PRC marketplace Stage: Approved for at least one indication by the NMPA.
$4.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a reverse stock split. SEC Form 8-K (Items 7.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio